SLC5A2 and heart failure: The effect of SGLT2 inhibitors on the composite of cardiovascular death or first hospitalization for heart failure was consistent across 14 clinically relevant subgroups, except for NYHA functional classification, (attenuated effect with NYHA III or IV compared to NYHA class II patients [HR, 0.86; 95% CI [0.77–0.95]]).